Navigation Links
Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
Date:8/1/2014

program at a particular stage in development.  Current development-stage programs include antisense drugs to treat SMA, ISIS-SMNRx, and myotonic dystrophy type 1, ISIS-DMPKRx.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO®, in the United States and other countries for the treatment of patients with homozygous FH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis' alliance with Biogen Idec, the discovery, development, activity, therapeutic and commercial potential and safety of ISIS-SMNRx and the discovery, development and therapeutic potential of an antisense drug for the treatment of spinal muscular atrophy.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cau
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014
2. Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results
3. Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014
4. Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs
5. Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results
6. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytrens Contracture In Japan
7. Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity
8. Access Pharmaceuticals Featured On OncLive.com
9. Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin
10. Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences
11. Cloud Pharmaceuticals Receives Phase I NSF SBIR Grant Valued at $150,000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 24, 2015 Introduction ... indication-specific planning tools for radiosurgery/SBRT   ... aimed at enhancing the workflow for difficult to ... in 2013 - comes full circle with the ... These new Elements enable on-the-fly generation of consistent ...
(Date:4/24/2015)... NORCROSS, Ga. , April 24, 2015 /PRNewswire/ ... ,s researchers, paper, that such was not the product of ... not form a reliable basis for allegations of ... shaky position on a false premise, or misguided ... In fact, these studies are contradicted by multiple ...
(Date:4/24/2015)... Hospira, Inc. (NYSE: HSP ... therapies, spoke about the importance of extrapolation in bringing ... (EGA) annual European Biosimilars Group conference in ... the publication of a pivotal white paper titled, ... of biosimilars." Speaking at the EGA ...
Breaking Medicine Technology:Brainlab Introduces New Generation of VMAT* for Brain and Spine at 3rd ESTRO in Barcelona 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 3Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 4Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 5Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7
... N.J., Jan. 18, 2011 MonoSol Rx, LLC ("MonoSol ... an amended patent infringement and false marking lawsuit today ... ; "BDSI"), MEDA Pharmaceuticals Inc. ("MEDA"), and Aveva Drug ... Court for the District of New Jersey. ...
... Calif., Jan. 18, 2011 Hotspur Technologies, Inc. announced ... & S Surgical Hospital in Monroe, Louisiana, successfully completed ... in an intervention to treat a blocked peripheral artery. ... of procedure confirms the ability of this device to ...
Cached Medicine Technology:MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc. 2First Hotspur Peripheral Angioplasty Case Completed 2First Hotspur Peripheral Angioplasty Case Completed 3
(Date:4/24/2015)... Anchor Health Administrators (Anchor), specialists in Long-Term ... their exclusive agreement with LTC Solutions for All LLC ... partner. , Anchor has more than 18 years of ... associations, and is currently the designated advocate for the ... Insurance member benefit. , “I am very pleased to ...
(Date:4/24/2015)... April 24, 2015 Insuranceautoquote.info has released ... car insurance premiums . , Lowering auto insurance ... quotes to simply find better offers for their financial ... and it does not require any registration. , ... coverage. There are multiple agencies that sell coverage and ...
(Date:4/24/2015)... April 24, 2015 Telematics Berlin is ... automakers, tier 1 & 2 suppliers, content providers, associations ... players in the value chain, see them converge in ... not only hear from those companies currently at the ... future partners. Working on customer centric products, ParkTAG are ...
(Date:4/24/2015)... Nisan Trotter is a personal trainer and ... along with the TROTFITNESS Fit Body Boot ... was awarded the Personal Trainer of the Year Award ... Summit is a business convention created by fitness industry ... Keuilian created the Summit to educate fitness professionals on ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Kessler Plastic ... the staff, Jamie Johansen. She will be in charge ... resources, patient relations, and reporting. Jamie will bring her ... surgery sector as the new Practice Manager. Her most ... and Practice Manager at American Laser Skincare. , ...
Breaking Medicine News(10 mins):Health News:Car Insurance Quotes Can Help Drivers Lower Their Premiums 2Health News:Telematics Berlin 2015’s inaugural European Automotive Start-Up Competition 2Health News:Telematics Berlin 2015’s inaugural European Automotive Start-Up Competition 3Health News:Lewisburg Fitness Trainer Named 2015 Personal Trainer of the Year 2Health News:Lewisburg Fitness Trainer Named 2015 Personal Trainer of the Year 3
... - CRH Medical Corporation,(CRM:TSX-V) announced today that it has ... Island. This Center is the Company,s first in the,state ... CRH has targeted for,expansion. The opening of this location ... Company,s total number of Centers to 14., According ...
... (IDF) BRIDGES translational research grant program will fund a ... for people at high-risk for getting type 2 diabetes ... develop a healthy lifestyle. , The National Hospital of ... Vietnam. Using diabetes risks questionnaires (1) , the investigators ...
... May 15 Gerson Lehrman Group, the world,s,leading ... a Web-based community devoted to providing patients with ... own healthcare.,iGuard.org provides personalized iGuard Risk Ratings, iGuard ... their experience with other registered,users who also want ...
... Pain is a chief reason that,patients seek ... these patients. Physicians must be able to determine ... their patients., To make clinicians aware of ... dual journals Current Clinical Practice and The,Journal of ...
... cancer patients and menopausal women, study finds , , THURSDAY, ... local anesthetic into the nerves of the neck that ... from hot flashes and sleep deprivation, a new study ... breast cancer, especially among women taking anti-estrogen drugs. These ...
... invites shareholders and investors to listen to a broadcast ... and a discussion,of the outlook for the fourth quarter., ... over the Internet on,Thursday, May 15, 2008 at 4:30 ... Company,s website at http://www.pro-dex.com . Mark Murphy,Chief Executive ...
Cached Medicine News:Health News:CRH Medical Corporation opens Center in New York 2Health News:International Diabetes Federation gives grant to diabetes screening & prevention program in Vietnam 2Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 2Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 3Health News:Treat Your Patients' Pain Effectively 2Health News:Hot Flashes Reduced by Neck Injection 2Health News:Hot Flashes Reduced by Neck Injection 3Health News:Pro-Dex, Inc. Announces Fiscal 2008 Third Quarter Financial Results Conference Call and Webcast 2
... now offers the first and only ... and monitoring of bladder cancer patients. ... quantitative microplate enzyme immunoassay that detects ... the urine of patients with bladder ...
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
... autoimmune testing feature single-well ANA screen and ... reflex tests including dsDNA, and 6 individual ... (La), Scl-70 and Jo-1. In addition, our ... of products for Cardiolipins (IgA, IgG, IgM), ...
Medicine Products: